Compare CDXS & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDXS | VNDA |
|---|---|---|
| Founded | 2002 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 256.3M | 301.1M |
| IPO Year | 2008 | 2005 |
| Metric | CDXS | VNDA |
|---|---|---|
| Price | $1.36 | $4.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $6.14 | ★ $11.75 |
| AVG Volume (30 Days) | ★ 636.5K | 598.5K |
| Earning Date | 11-05-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.82 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $138,590,000.00 | ★ $216,105,000.00 |
| Revenue This Year | $4.97 | $15.16 |
| Revenue Next Year | $18.69 | $35.50 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 32.30 | 8.72 |
| 52 Week Low | $0.96 | $4.27 |
| 52 Week High | $2.98 | $9.91 |
| Indicator | CDXS | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 44.39 | 39.46 |
| Support Level | $1.38 | $4.45 |
| Resistance Level | $1.76 | $5.37 |
| Average True Range (ATR) | 0.08 | 0.16 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 54.35 | 8.16 |
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.